Tag: Darzalex
-

Johnson & Johnson Wins EU Approval for Tecvayli Plus Darzalex in Multiple Myeloma
The European Commission approved Tecvayli plus Darzalex for adults with relapsed or refractory multiple myeloma after at least one prior therapy, supported by Phase 3 MajesTEC-3 data showing an 83% reduction in the risk of progression or death versus DPd or DVd.
-

Bristol Myers Squibb (BMS) Wins FDA Approval for the First CELMoD Therapy in Multiple Myeloma
The FDA granted accelerated approval to Bristol Myers Squibb’s Zenbexus (iberdomide) as part of a three-drug regimen for previously treated multiple myeloma, marking the first approval of a CELMoD therapy.